Sunday, October 01, 2017 1:09:24 PM
The ongoing argument, I've suggested, needs to be stated in terms of the overall potential of the company. It's makes some sense to gather data on cancers we treat with some guesstimates of likelihood of success and market penetration.
- incidence of cancers our constructs can treat (# of new cases/yr)
- % of those cancers that express the antigens we target (not all do)
- Throw in an uncertainty multiplier (for all cancers NOT far along in clinical development I used a 10% likelihood of success, for the ones further along I used 80%.)
- Throw in a potential market penetration - 50% across the board)
- Throw in what the charge/treatment might be - 50K across the board (personally I think this will be more.)
- Do some math. (Thank goodness for excel!)
These numbers reflect the US and EU only. I think patients in South America will want the treatments if successful, along with China, Russia, etc..... You get my point.
The speadsheet I created is actually much larger, but alas doesn't copy well into this site. I tried my best to make it readable. (If anyone knows how let me know and I'll repost.)
So for S***s and giggles this morning I did just that.
Tumor Type % of Tumors Expressing antigen Total Total w/Antigen Uncertainty Multiplyer Potential Pts Market Penetration Revenue
Bladder 12.4% 203000 25172 0.1 2517 1259 $62,930,000
Gallbladder 9.8% 31700 3107 0.1 311 155 $7,766,500
Uterine 3.0% 204700 6141 0.1 614 307 $15,352,500
Testicular 2.4% 51800 1243 0.1 124 62 $3,108,000
Esophageal 25.0% 51900 12975 0.1 1298 649 $32,437,500
Osteosarcoma 80.0% 3000 2400 0.8 1920 960 $48,000,000
Breast 20.0% 719100 143820 0.1 14382 7191 $359,550,000
Cervical 70.0% 71000 49700 0.8 39760 19880 $994,000,000
Head and Neck 25.0% 145000 36250 0.1 3625 1813 $90,625,000
NSCLC 15.0% 506000 75900 0.1 7590 3795 $189,750,000
Anal 95.0% 21500 20425 0.1 2043 1021 $51,062,500
Prostate Cancer 100.0% 578000 578000 0.1 57800 28900 $1,445,000,000
$3,299,582,000
This estimate does NOT take into account HOT, DUAL, or other patented constructs not in clinical development.
Again, let me repeat, this is a very conservative estimate that anticipates only a 10% likelihood of success and a 50% market penetration of most of these constructs.
As you can see, this very conservative estimate of the potential of Advaxis is over 3B. If you use a multiplier for the sale of 3x it can easily sell for over 9B.
I really, really hope this post helps quiet those who think we should sell for 1B or less. That number is totally, and now irrefutably, ridiculous.
Shameless request for a mod - please pin this.
Recent ADXS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:13:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:30:45 PM
- Form DEFM14C - Definitive information statement relating to merger or acquisition • Edgar (US Regulatory) • 03/05/2024 01:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:30:46 PM
- Form PREM14C - Preliminary information statements relating to merger or acquisition • Edgar (US Regulatory) • 02/20/2024 10:22:48 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:26:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 07:16:21 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/12/2024 04:58:05 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 01:27:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:51:21 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/03/2024 09:18:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 02:04:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/21/2023 02:00:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 02:00:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:04:59 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 09:01:18 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:46:10 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:45:26 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:43:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 11:08:02 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/31/2023 11:05:10 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 10/23/2023 10:45:21 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM